Vertical Soft Tissue Augmentation With Tent Pole Technique and Its Influence on Marginal Bone Los… (NCT07018531) | Clinical Trial Compass
Not Yet RecruitingNot Applicable
Vertical Soft Tissue Augmentation With Tent Pole Technique and Its Influence on Marginal Bone Loss Around Dental Implants
Spain, Tunisia112 participantsStarted 2025-07
Plain-language summary
This study aims to evaluate the effectiveness of the tent pole technique in vertical peri-implant soft tissue augmentation and to assess its impact on marginal bone loss. Additionally, the adjunctive use of platelet-rich fibrin and photobiomodulation will be explored to determine their influence on the clinical outcomes of this procedure.
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Participants must be over 18 years of age. They should be legally capable of adhering to study protocols, which include maintaining proper oral hygiene, attending all scheduled follow-up visits, fully understanding the proposed surgical procedures, and signing the informed consent form.
* single edentulous sites in the premolar and/or molar region of the mandible.
* Vertical gingival thickness must be more than 1 mm and less than or equal to 2 mm.
* A minimum of 2 mm of attached gingiva should be present on both the buccal and lingual sides of the implant sites.
* Buccal bone thickness must be at least 1.5 mm.
Exclusion Criteria:
* Presence of general contraindications for dental implants or surgical interventions.
* Heavy smoking, defined as more than 10 cigarettes daily, including pipe, vape or cigar use.
* Poor oral hygiene, characterized by probing depths greater than 4 mm in adjacent teeth, and a full mouth plaque score (FMPS) or full mouth bleeding score (FMBS) exceeding 25% after the pre-treatment phase.
* Guided bone regeneration at the implant site.
* History of conditions or diseases that compromise bone metabolism (e.g. Paget's disease, osteoporosis) or current use of medications that may affect bone metabolism (e.g. bisphosphonates).
* History of cancer or prior radiotherapy or chemotherapy treatments for malignancy.
* Uncontrolled diabetes.
* Current pregnancy or breastfeeding status.
* Allergies to any products involved in the study.